Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Anika Therapeutics, Inc. (ANIK)
|
Add to portfolio |
|
|
|
| Price: |
$36.54
| | Metrics |
| OS: |
14.6
|
M
| |
-7
|
% ROE
|
| Market cap: |
$535
|
M
| |
-14
|
% ROIC
|
|
Net cash:
|
$102
|
M
| |
$6.96
|
per share
|
|
EV:
|
$433
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($22.2)
|
M
| |
|
|
|
EBIT
|
($28.6)
|
M
| |
|
|
| EPS |
($1.52)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 156.2 | 147.8 | 130.5 | 114.6 | 105.6 | 113.4 | 103.4 | 93.0 |
| Revenue growth | 5.7% | 13.3% | 13.8% | 8.6% | -6.9% | 9.7% | 11.2% | -11.9% |
| Cost of goods sold | 70.4 | 72.7 | 68.8 | 29.8 | 31.3 | 27.4 | 24.0 | 21.1 |
| Gross profit | 85.8 | 75.1 | 61.6 | 84.8 | 74.3 | 86.1 | 79.4 | 71.9 |
| Gross margin | 54.9% | 50.8% | 47.3% | 74.0% | 70.4% | 75.9% | 76.8% | 77.4% |
| Selling, general and administrative | 84.8 | 74.1 | 60.1 | 35.0 | 34.3 | 21.5 | 18.0 | 14.8 |
| Research and development | 28.2 | 27.3 | 23.4 | 16.7 | 18.2 | 18.8 | 10.7 | 9.0 |
| EBITA | -11.6 | -11.1 | -14.5 | 35.2 | 22.7 | 46.7 | 51.7 | 49.2 |
| EBITA margin | -7.4% | -7.5% | -11.1% | 30.8% | 21.6% | 41.2% | 50.0% | 52.9% |
| Amortization of intangibles | 7.8 | 7.4 | | 1.0 | 1.0 | 1.0 | 1.1 | 1.1 |
| EBIT | -19.4 | -18.5 | -14.5 | 34.2 | 21.7 | 45.7 | 50.6 | 48.1 |
| EBIT margin | -12.4% | -12.5% | -11.1% | 29.9% | 20.6% | 40.3% | 49.0% | 51.8% |
| Pre-tax income | -18.7 | 2.4 | -28.6 | 36.1 | 23.2 | 46.2 | 50.9 | 48.3 |
| Income taxes | -3.9 | -1.7 | -4.6 | 8.9 | 4.5 | 14.4 | 18.3 | 17.5 |
| Tax rate | 20.7% | | 16.2% | 24.7% | 19.3% | 31.1% | 36.0% | 36.3% |
| Net income | -14.9 | 4.1 | -24.0 | 27.2 | 18.7 | 31.8 | 32.5 | 30.8 |
| Net margin | -9.5% | 2.8% | -18.4% | 23.7% | 17.7% | 28.1% | 31.5% | 33.1% |
| |
| Diluted EPS | ($1.02) | $0.28 | ($1.69) | $1.89 | $1.27 | $2.11 | $2.15 | $2.01 |
| Shares outstanding (diluted) | 14.6 | 14.6 | 14.2 | 14.4 | 14.7 | 15.1 | 15.1 | 15.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|